After PCI in patients with ACS, short-duration DAPT followed by P2Y12 inhibitor monotherapy vs. standard DAPT reduces NACE.

Short-duration DAPT followed by P2Y12 inhibitor monotherapy significantly reduces NACE compared to standard DAPT in patients with ACS after PCI.

• Why it matters: Reducing adverse events after PCI in ACS patients is critical for improving outcomes and minimizing bleeding risks associated with prolonged dual antiplatelet therapy.
• What they did: The study compared short-duration DAPT with subsequent P2Y12 monotherapy versus standard DAPT, analyzing NACE rates in this patient population.
• The result: Findings demonstrate that the shorter DAPT regimen decreases NACE, suggesting a safer and potentially more effective antiplatelet strategy post-PCI in ACS patients.